Skip to main content
fda approved image

Lupin obtains tentative OK for generic Qtern

Dapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.
Levy

Lupin has received tentative approval from the Food and Drug Administration for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg, which is the generic of AstraZeneca’s Qtern. 

Dapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.

This product will be manufactured at Lupin’s Pithampur facility in India.

[Read more: Lupin receives FDA OK for generic Banzel]

Dapagliflozin and Saxagliptin Tablets had a market value of roughly $5 million, per IQVIA  November 2023 data.

[Read more: Lupin receives FDA nod for 3 generics]

X
This ad will auto-close in 10 seconds